(VIANEWS) – Shares of Novavax (NASDAQ: NVAX) fell by a staggering 35.59% in 30 days from $56.54 to $36.42 at 10:46 EST on Thursday, after two sequential sessions in a row of gains. NASDAQ is rising 0.94% to $12,548.78, following the last session’s upward trend.

Novavax’s last close was $37.07, 86.66% under its 52-week high of $277.80.

Novavax, Inc. is a biotechnology firm that focuses on vaccine development and commercialization. This company addresses health and prevents serious infections. Among the vaccine candidates are NVX–CoV2373, a candidate coronavirus vaccine, which is currently in 2 Phase III trials and 1 Phase IIb trial. NanoFlu is a candidate nanoparticle seasonal quadrivalent flu vaccine that is in Phase 3. ResVax is a candidate respiratory syncytialvirus (RSV), fusion (F), protein nanoparticle vaccine. The company is currently developing RSV F vaccine, which is being tested in the Phase II clinical trials for adults aged 60 years or older. It also has a Phase I clinical trial in pediatrics. Takeda Pharmaceutical Company Limited has signed a cooperation agreement for the production, commercialization, and development of NVXCoV2373 (a COVID-19 candidate vaccine). Novavax, Inc., was founded in 1987. It is located in Gaithersburg, Maryland.


Today’s last reported volume for Novavax is 691891 which is 90.82% below its average volume of 7537603.

The company’s growth estimates for the ongoing quarter and the next is 215.8% and 247.6%, respectively.

Novavax’s Revenue

Year-on-year quarterly revenue growth declined by 37.6%, now sitting on 1.29B for the twelve trailing months.


Novavax’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.08%, a negative 2.13%, and a positive 6.59%, respectively.

Novavax’s highest amplitude of average volatility was 2.31% (last week), 4.91% (last month), and 6.59% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Novavax’s stock is considered to be oversold (<=20).

Novavax’s Stock Yearly Top and Bottom Value

Novavax’s stock is valued at $36.42 at 10:46 EST, way under its 52-week high of $277.80 and higher than its 52-week low of $34.88.

Novavax’s Moving Average

Novavax’s value is way below its 50-day moving average of $51.97 and way below its 200-day moving average of $89.96.

Previous days news about Novavax (NVAX)

  • Novavax covid vaccine authorized for teens in U.S.. According to MarketWatch on Monday, 22 August, “The Food and Drug Administration authorized Novavax Inc.’s COVID-19 vaccine for use in U.S. teenagers on Friday. “

More news about Novavax (NVAX).


Please enter your comment!
Please enter your name here